Fig. 5: The hexon modification enables systemic administration of ICVB-1042. | Communications Biology

Fig. 5: The hexon modification enables systemic administration of ICVB-1042.

From: Nonclinical characterization of ICVB-1042 as a selective oncolytic adenovirus for solid tumor treatment

Fig. 5

a In vitro binding of ICVB-1042 and ICVB-1042wt-hexon to human FX was assessed by ELISA. Representative of two independent experiments; nude, female mice 6–8 weeks old. b Survival of nude, female, 6–8 week old mice bearing SW780 bladder tumor xenograft after IV treatment with ICVB-1042 (blue), ICVB-1042wt-hexon (yellow), or vehicle (black). Vertical dash lines represent dosing days. n = 8 mice per group. c Levels of liver enzymes AST, ALT, and ALP in plasma were monitored in C57BL/6 male and female mice, which were 6–7 weeks old at implant, 24 h after IV administration of ICVB-1042 (dark blue, 1E11 VP/dose; light blue, 1E10 VP/dose), Wt Ad5 (red, 1E10 VP/dose), or vehicle (black) in C57BL/6 mice. n = 8 mice per group.

Back to article page